Literature DB >> 9716174

Treatment of a patient with Bernard-Soulier syndrome and recurrent nosebleeds with recombinant factor VIIa.

M Peters, H Heijboer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9716174

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN： 0340-6245            Impact factor:   5.249


× No keyword cloud information.
  10 in total

Review 1.  The use of recombinant activated coagulation factor VII for spine surgery.

Authors:  Richard B Weiskopf
Journal:  Eur Spine J       Date:  2004-05-25       Impact factor: 3.134

2.  Severe recurrent gastrointestinal bleeding due to angiodysplasia in a Bernard-Soulier patient: an onerous medical concomitance.

Authors:  Osman Yüksel; Seyfettin Köklü; Engin Uçar; Nurgül Saşmaz; Burhan Sahin
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

Review 3.  Recombinant factor VIIa: a review on its clinical use.

Authors:  Massimo Franchini
Journal:  Int J Hematol       Date:  2006-02       Impact factor: 2.490

Review 4.  The use of recombinant activated factor VII in platelet disorders: a critical review of the literature.

Authors:  Massimo Franchini
Journal:  Blood Transfus       Date:  2009-01       Impact factor: 3.443

5.  Non-myeloablative conditioning with busulfan before hematopoietic stem cell transplantation leads to phenotypic correction of murine Bernard-Soulier syndrome.

Authors:  S Kanaji; S A Fahs; J Ware; R R Montgomery; Q Shi
Journal:  J Thromb Haemost       Date:  2014-08-26       Impact factor: 5.824

Review 6.  The emerging role of recombinant-activated factor VII in neurocritical care.

Authors:  Matthew E Fewel; Paul Park
Journal:  Neurocrit Care       Date:  2004       Impact factor: 3.210

7.  Correction of murine Bernard-Soulier syndrome by lentivirus-mediated gene therapy.

Authors:  Sachiko Kanaji; Erin L Kuether; Scot A Fahs; Jocelyn A Schroeder; Jerry Ware; Robert R Montgomery; Qizhen Shi
Journal:  Mol Ther       Date:  2011-11-01       Impact factor: 11.454

8.  Novel therapeutic approach for hemophilia using gene delivery of an engineered secreted activated Factor VII.

Authors:  Paris Margaritis; Valder R Arruda; Majed Aljamali; Rodney M Camire; Alexander Schlachterman; Katherine A High
Journal:  J Clin Invest       Date:  2004-04       Impact factor: 14.808

9.  Newly diagnosed congenital factor VII deficiency and utilization of recombinant activated factor VII (NovoSeven(®)).

Authors:  Nicole S Bartosh; Tara Tomlin; Christian Cable; Kathleen Halka
Journal:  Clin Pharmacol       Date:  2013-03-15

Review 10.  Clinical use of recombinant human activated factor VII (rFVIIa) in the prevention and treatment of bleeding episodes in patients with Glanzmann's thrombasthenia.

Authors:  Man-Chiu Poon
Journal:  Vasc Health Risk Manag       Date:  2007
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.